Bookmark and Share

Robert R. Conley M.D.

Academic Title: Adjunct Professor
Primary Appointment: Psychiatry
Location: 701 W. Pratt St., 388 (MPRC)
Phone: (410) 402-6860

Personal History:

Professional History

  • Extramural Fellow, NIMH/Univ of Pittsburgh 1987-88
  • Chief Resident, University of Pittsburgh, Psychiatry, 1986
  • Residency, University of Pittsburgh, Psychiatry, 1985
  • M.D., University of Maryland at Baltimore, 1981
  • B.A., Johns Hopkins University, Natural Science, History of Science, 1977

Research Interests:

My work is focused on comparing the clinical effects of newer antipsychotics in people with schizophrenia, including those who are refractory to therapy using trials with a similar strategy to the one that defined clozapine as a differentially effective antipsychotic. Our group performs large clinical trials, outcome studies and human post-mortem studies. Our group provides the clinical characterization of the subjects in the Maryland Brain Collection. We have a primary interest in the binding patterns of antipsychotic medication in the human brain and antipsychotic-induced changes in the ultrastructure of the human synapse. We also actively work in the area of research ethics, particularly in the area of evaluation of ability to consent to research trials.

My past work has included double-blind evaluations of remoxipride and olanzapine, multiple studies with clozapine and, most recently completed, a double-blind evaluation of quetiapine, risperidone or fluphenazine. We have also begun to do extensive work in adjunct pharmacotherapy for schizophrenia. Our group now is conducting five trials employing adjunct pharmacotherapy in partially responsive people with schizophrenia: glycine or cycloserine for negative symptoms, risperidone in partial clozapine responders, preclamol in partial clozapine responders, galantamine in people with schizophrenia and persistent cognitive deficits and atomoxetine in people with schizophrenia and persistent cognitive deficits.

I am the Chairman of the Institutional Review Board for the National Institute of Drug Abuse; member of the Executive Committee for University of Maryland, Baltimore Institutional Review Board; Director of Research, Unit 364, Perry Point Veterans Affairs Medical Center, Perryville, Maryland; and Member, Human Research Policy & Oversight Committee, University of Maryland, Baltimore.


Conley RR, Kelly DL, Beason-Held LL, Holcomb HH, Richardson CM. The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of Psychopharmacology (oxford, England). 18(3), 429-31. Sep 2004.

Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: A double-blind crossover study. Journal of Clinical Psychopharmacology. 23(6), 668-71. December 2003.

Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. 15(1), 23-31. March 2003.

Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. The American Journal of Psychiatry. 158(5), 765-74. May 2001.

Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lenert LA, Mahmoud R, Marder SR, Neumann PJ. The heterogeneity of schizophrenia in disease states. Schizophrenia Research. 71(1), 83-95. November 2004.

Love RC, Conley R. Long-acting risperidone injection. American Journal of Health-system Pharmacy : Ajhp : Official Journal of the American Society of Health-system Pharmacists.. 61(17), 1792-800. September 2004.

Kelly DL, Shim JC, Feldman SM, Yu Y, Conley RR. Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death. Journal of Psychiatric Research. 38(5), 531-6. Sep-O 2004. Abstract

Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, Conley R, Scully P, Chue PS, Lachaux B. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Services (washington, D.c.). 55(9), 997-1005. Sep 2004.

Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Conley RR. Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study. Archives of General Psychiatry. 61(7), 685-93. July 2004.

Kim YH, Shim JC, Kelly DL, Lee JG, Seo YS, Conley RR. Cortisol response to buspirone in extended abstinent alcoholics. Alcohol and Alcoholism (oxford, Oxfordshire). 39(4), 287-9. 2004.

Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller del D, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry. 65(4), 500-8. 2004.

Kelly DL, Love RC, MacKowick M, McMahon RP, Conley RR. Atypical antipsychotic use in a state hospital inpatient adolescent population. Journal of Child and Adolescent Psychopharmacology. 14(1), 75-85. 2004.

Lambert T, Kelly DL, Alcock S, Conley RR. Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. Journal of Clinical Psychopharmacology. 24(1), 91-3. 2004.
Dwivedi Y, Rizavi HS, Shukla PK, Lyons J, Faludi G, Palkovits M, Sarosi A, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biological Psychiatry. 55(3), 234-43. February 2004.

Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. Journal of Clinical Psychiatry. 65(1), 120-31. January 2004.

Wehring HJ, Kelly DL, Love RC, Conley RR. Deaths from diabetic ketoacidosis after long-term clozapine treatment. The American Journal of Psychiatry. 160(12), 2241-2. 2003.

Nelson MW, Reynolds RR, Kelly DL, Conley RR. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clinical Neuropharmacology. 26(6), 297-8. 2003.

Shim JC, Kelly DL, Kim YH, Yoon YR, Park JH, Shin JG, Conley RR. Fluoxetine augmentation of haloperidol in chronic schizophrenia. Journal of Clinical Psychopharmacology. 23(5), 520-2. October 2003.

Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists.. 15(3-4), 181-6. 2003.

Kelly DL, Conley RR. Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophrenia Research. 63(1-2), 195-6. September 2003.

Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Roberts RC, Conley RR, Tamminga C. Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. Journal of Psychiatric Research. 37(5), 421-32. 2003.

Kirkpatrick B, Messias NC, Conley RR, Roberts RC. Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia. Journal of Nervous and Mental Disease. 191(9), 563-7. September 2003.

Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine. Journal of Clinical Psychiatry. 64(9), 1133-4. September 2003.

Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Archives of General Psychiatry. 60(8), 804-15. August 2003.

Lambert TJ, Cock N, Alcock SJ, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacology. 18(5), 405-11. July 2003.

Dwivedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Archives of General Psychiatry. 60(3), 273-82. March 2003.

Kelly DL, Gale EA, Conley RR. Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 48(2), 111-4. March 2003.
Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. Clinical guidelines: Dosing and switching strategies for long-acting risperidone. Journal of Clinical Psychiatry. 64 Suppl 16, 41-6. 2003.

Kreyenbuhl JA, Kelly DL, Conley RR. Circumstances of suicide among individuals with schizophrenia. Schizophrenia Research. 58(2-3), 253-61. December 2002.

Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. mRNA and protein expression of selective alpha subunits of G proteins are abnormal in prefrontal cortex of suicide victims. 27(4), 499-517. October 2002.

Conley RR, Kelly DL. Current status of antipsychotic treatment. Curr Drug Target Cns Neurol Disord. 1(2), 123-8. April 2002.
Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. The American Journal of Psychiatry. 159(4), 554-60. April 2002.

McMahon RP, Kelly DL, Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials. 26(4), 537-45. April 2002.

Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C, Roberts RC, Conley RR, Tamminga CA. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. The American Journal of Psychiatry. 159(3), 419-29. March 2002.

Dwivedi Y, Conley RR, Roberts RC, Tamminga CA, Pandey GN. [(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. The American Journal of Psychiatry. 159(1), 66-73. January 2002.

Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biological Psychiatry. 50(11), 898-911. December 2001.

Avila MT, Conley RR, Carpenter WT. A comparison of symptom provocation procedures in psychiatry and other areas of medicine: implications for their ethical use in research. Biological Psychiatry. 50(7), 479-86. 2001.

Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating from clozapine. The American Journal of Psychiatry. 158(8), 1329-30. August 2001.

Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. Journal of Neurochemistry. 77(3), 916-28. May 2001.

Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatric Services (washington, D.c.). 52(5), 676-8. 2001.

Conley RR. Evaluating clinical trial data: outcome measures. Journal of Clinical Psychiatry. 62 Suppl 9, 23-6; discussion 27-. 2001.

Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. The American Journal of Psychiatry. 157(7), 1141-9. 2000.

Carpenter WT Jr, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS. Decisional capacity for informed consent in schizophrenia research. Archives of General Psychiatry. 57(6), 533-8. June 2000.
Carpenter WT Jr, Conley R, Kirkpatrick B. On schizophrenia and new generation drugs. 22(6), 660-4. June 2000.

Conley RR. Risperidone side effects. Journal of Clinical Psychiatry. 61 Suppl 8, 20-3; discussion 24-. 2000.
Conley RR, Meltzer HY. Adverse events related to olanzapine. Journal of Clinical Psychiatry. 61 Suppl 8, 26-9; discussion 30. 2000.